ARCT — Arcturus Therapeutics Holdings Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1768224 ·
Last close
$7.97
Market Cap
$229.72M
52W High
$17.96
52W Low
$5.50
ADV30
654,974
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 16,852,000 — -9,185,000 -7,414,000 215,316,000 184,817,000 46,589,000
Jun 2026 880,000 — -25,545,000 -23,785,000 224,310,000 191,483,000 52,502,000
Mar 2026 610,000 — -28,931,000 -26,964,000 245,411,000 211,375,000 54,049,000
Dec 2025 3,081,000 — -31,307,000 -29,079,000 271,148,000 230,909,000 57,163,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-72,729,000
Investing CF
$-41,000
Financing CF
$12,929,000
CapEx
$-318,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.31
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-565,339,000
Inventory
—
Receivables
$1,813,000
ST Investments
—
EBIT TTM
$-91,809,000
Pretax Income TTM
$-93,280,000
Interest Exp TTM
—
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$30,513,000
EBITDA
$-92,357,000
Free Cash Flow
$19,258,624
Enterprise Value
$127,998,352
Total Cash
$184,816,992
Total Debt
$18,244,000
Shares Out
28,822,514
Trailing EPS
$-3.10
Book Value
$5.93
ROE
-44.4%
ROA
-23.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 67,221,000 -76,260,000 -65,783,000 271,148,000 57,163,000 213,985,000 -74,271,000
Dec 2024 138,389,000 -95,669,000 -80,941,000 344,069,000 103,091,000 240,978,000 -59,747,000
Dec 2023 157,748,000 -78,205,000 -29,725,000 429,402,000 150,889,000 278,513,000 -18,099,000
Dec 2022 205,755,000 12,177,000 9,349,000 450,387,000 180,075,000 270,312,000 31,993,000

TTM Snapshot

Revenues TTM
$29,368,000
NetIncome TTM
$-93,276,000
OpCashFlow TTM
—
Assets (Latest)
$224,310,000
Forward EPS
$-3.41

Max Pain — expiry 2026-12-18

max pain strike: $12.50 · spot: $8.04 · call oi: 638 · put oi: 779
Expected Move to 2026-12-18: ±$3.38 (41.98%) — implied range $4.66 – $11.41 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VNDA Vanda Pharmaceuticals Inc. $230.39M $3.81 —
FTH Faeth Therapeutics, Inc. $233.63M $9.04 —
BIOA BioAge Labs, Inc. $234.35M $5.10 —
IMRX Immuneering Corp $224.08M $3.46 —
RCKT ROCKET PHARMACEUTICALS, INC. $235.60M $2.11 —

News headlines (Yahoo Finance, 1h cache)

Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration
2026-11-16 13:30 · Yahoo
What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call
2026-11-06 03:14 · Yahoo
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
2026-10-26 20:01 · Yahoo
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
2026-09-25 03:02 · Yahoo
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
2026-09-23 20:01 · Yahoo
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
2026-09-18 13:00 · Yahoo
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
2026-08-31 20:01 · Yahoo
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
2026-08-27 13:55 · Yahoo
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
2026-08-12 01:04 · Yahoo
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
2026-11-05 21:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.